Checkpoint Therapeutics, Inc. (CKPT) has a consensus analyst rating of Buy, based on 7 analysts covering the stock. Of those, 5 recommend buying, 2 recommend holding, and 0 recommend selling.
The analyst consensus price target for CKPT is $4.10, representing a -3.8% downside from the current price of $4.26. Price targets range from a low of $4.10 to a high of $4.10.
